This early phase I trial studies the side effects of personalized vaccine in treating patients with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.
Patients undergo collection of blood and bone marrow for making the vaccine. Patients then receive personalized vaccine SC on days 1 and 15 of cycles 1-2 and on day 1 of cycles 3-6. Patients also receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, participants are followed up at 3 and 12 months.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Evidence of myeloma defining events due to underlying plasma cell proliferative disorder meeting at least one of the following
Prior or concurrent systemic treatment for SMM
Read the latest news and updates on this trial.
October 28, 2021
Many approaches are attempting to prevent smoldering myeloma from progressing to active myeloma. One such approach is a personalized vaccine being developed at MD Anderson Cancer Center.